Omexa Formulary Pvt Ltd, based in Chennai, has announced plans to establish a new manufacturing unit for monoclonal antibodies and formulation products.
They will build the facility with an investment of ₹95 crore near Tindivanam, south of Chennai.
The proposed site, spanning four acres, is located in TANSIDCO Industrial Park in Pellakuppam village, Villupuram district, Tamil Nadu.
Production Capacity and Product Range
The facility will boast an annual production capacity of 520 kg of monoclonal antibodies and 1,64,000 units of formulation products per month.
Omexa aims to produce thirty monoclonal antibody products, along with two formulation products: prefilled syringes, vials, and lyophilised vials. The strategic move aligns with the growing demand for affordable monoclonal antibody treatments, particularly for cancer patients.
Boosting ‘Make in India’ and Import Substitution
The project comes at a time when there is a strong push for import substitution under the ‘Make in India’ initiative.
The API and API intermediates industry is growing at an average annual rate of 12%. Omexa is ready to capitalize on this momentum.
The company plans to leverage this opportunity to supply monoclonal antibodies at reduced costs. It makes them more affordable for both domestic and international markets.
Future Growth Potential
Omexa’s new manufacturing unit is a strategic response to the robust growth in the monoclonal antibody sector.
As reported by thehindubusinessline.com, the industry is projected to continue expanding over the next five to ten years. Omexa Formulary aims to meet this demand with its cost-effective offerings. This will reinforce its position in the global market.
